CN104306437B - A kind of for Chinese medicinal granular formulation treating cardiovascular disease and preparation method thereof - Google Patents
A kind of for Chinese medicinal granular formulation treating cardiovascular disease and preparation method thereof Download PDFInfo
- Publication number
- CN104306437B CN104306437B CN201410321506.2A CN201410321506A CN104306437B CN 104306437 B CN104306437 B CN 104306437B CN 201410321506 A CN201410321506 A CN 201410321506A CN 104306437 B CN104306437 B CN 104306437B
- Authority
- CN
- China
- Prior art keywords
- extract
- radix
- chinese medicine
- weight portion
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- 238000009472 formulation Methods 0.000 title abstract description 8
- 239000000284 extract Substances 0.000 claims abstract description 45
- 239000003814 drug Substances 0.000 claims abstract description 42
- 239000002671 adjuvant Substances 0.000 claims abstract description 20
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 19
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 19
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 5
- 108010011485 Aspartame Proteins 0.000 claims abstract description 4
- 229920000881 Modified starch Polymers 0.000 claims abstract description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims abstract description 4
- 229960003438 aspartame Drugs 0.000 claims abstract description 4
- 235000010357 aspartame Nutrition 0.000 claims abstract description 4
- 239000000605 aspartame Substances 0.000 claims abstract description 4
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 241001072909 Salvia Species 0.000 claims description 3
- 235000017276 Salvia Nutrition 0.000 claims description 3
- 241000304195 Salvia miltiorrhiza Species 0.000 claims description 3
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000007779 soft material Substances 0.000 claims description 3
- 229930189533 tanshinol Natural products 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 229940126678 chinese medicines Drugs 0.000 abstract description 3
- 241000208340 Araliaceae Species 0.000 description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 235000008434 ginseng Nutrition 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 208000026106 cerebrovascular disease Diseases 0.000 description 7
- 230000002526 effect on cardiovascular system Effects 0.000 description 7
- 208000029078 coronary artery disease Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 206010008190 Cerebrovascular accident Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000007574 infarction Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000000115 thoracic cavity Anatomy 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 241000756943 Codonopsis Species 0.000 description 2
- 241000218176 Corydalis Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000009877 shengmai Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 210000000876 intercostal muscle Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 description 1
- QJVXKWHHAMZTBY-KSXIZUIISA-N syringin Natural products COc1cc(C=CCO)cc(OC)c1O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O QJVXKWHHAMZTBY-KSXIZUIISA-N 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of for Chinese medicinal granular formulation treating cardiovascular disease and preparation method thereof, belong to the field of Chinese medicines.The Chinese medicinal granular formulation of the present invention is made up of Chinese medicine extract and adjuvant.The weight ratio of described Chinese medicine extract and adjuvant is 10:0.8～1.5；Described Chinese medicine extract by weight portion is: Radix Salviae Miltiorrhizae 30 parts, Radix Notoginseng 10 parts and Radix Et Caulis Acanthopanacis Senticosi 20 parts are made, and described adjuvant is the hydroxypropyl methyl cellulose of the pregelatinized Starch of 1～5 weight portion, the HP-β-CD of 5～10 weight portions, the Aspartame of 0.5 weight portion and 1～5 weight portion.
Description
Technical field
The present invention relates to a kind of for Chinese medicinal granular formulation treating cardiovascular disease and preparation method thereof, belong to the field of Chinese medicines.
Background technology
According to China's Epidemiological study, no matter in rural area or city over nearly 50 years, the M & M of cardiovascular and cerebrovascular disease is all in rising trend.50-60 age China population cause of death cardiovascular disease and cerebrovascular occupy the five or six respectively, then rise to the two or three respectively after 1970, and cardiovascular and cerebrovascular disease died has accounted for whole disease causes of the death first.China is part proportioning of total dead population because cardiovascular and cerebrovascular disease died accounts for, risen to the 42.6% of calendar year 2001 by the 12.07% of nineteen fifty-seven, person reaches 2,000,000 to die from cardiovascular and cerebrovascular disease every year, though separately there being some patients to survive through rescue, but majority leaves deformity, can't take care of oneself, cause serious burden to relatives and society.Cardiovascular and cerebrovascular disease Ye Shi western countries crowd's main causes of death.Speculating according to current existing epidemiologic data, advancing of disease trend is: to the year two thousand twenty, and the human diseases cause of the death puts in order will great change, but coronary heart disease and apoplexy will be first and seconds of mankind's cause of the death.Till that time, estimation whole world coronary heart disease death number will increase to 11,000,000 from the 6300000 of nineteen ninety；Apoplexy increases to 7,700,000 from 4,400,000.In 30 years, blood circulation Disease structure will increase 59.6%, and coronary heart disease and apoplexy increase 74.6% and 75% respectively.These data absolutely prove, cardiovascular and cerebrovascular disease is not only the principal disease of harm human health, especially at present and in following 20 years, the mankind are lethal, " number one killer " disabled.
In the medicine of cardiovascular and cerebrovascular disease, the application of Chinese medicine and western medicine emphasizes particularly on different fields, and Chinese medicine also takes up the bigger market share with the advantage that its side effect is little.Such as: the Yiqi Huoxue Recipe that is made up of Radix Ginseng, Radix Codonopsis, Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, Flos Carthami [Zhu Weifeng, Shandong College of Traditional Chinese Medicine's journal, 1994,18 (5)]；Added Radix Salviae Miltiorrhizae by SHENGMAI YIN, red stilbene SHENGMAI YIN that Radix Ginseng, Radix Notoginseng, Flos Carthami, Rhizoma Corydalis, Fructus Crataegi form, [Chen Yuchun, the bright traditional Chinese medical science, 1999,14 (5)]；The coronary heart disease being made up of Radix Ginseng, Radix Codonopsis, Radix Ophiopogonis, Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, Lignum Dalbergiae Odoriferae substantially square [Wang Jinrong etc., Liaoning Journal of Traditional Chinese Medicine, 2001,28 (8)]；The Shuxintongmai sheet that is made up of Radix Salviae Miltiorrhizae, Rhizoma Corydalis, Radix Ginseng, Radix Notoginseng, Rhizoma Chuanxiong, Radix Angelicae Sinensis [Wang Xiue etc., Shandong journal of Chinese medicine, 1997,16 (8)]；Etc..But above clinical prescription and Chinese patent medicine all have certain weak point, or are partial to QI invigorating, or relatively activate yang, or relatively invigorate blood circulation, and are popularized in an all-round way clinically.And dosage form mostly is traditional conventional tablet, capsule etc., production technology is more backward, and active constituent content is low, without quality control standard, therefore, the Chinese medicine utilizing the new treatment cardiovascular disease particularly coronary heart disease of new technology development is the target that numerous medical personal make great efforts.
Three ginseng electuaries, are made up of Radix Salviae Miltiorrhizae, Radix Et Caulis Acanthopanacis Senticosi and Radix Notoginseng, and the weight proportion between three is followed successively by 25:1:1.Radix Et Caulis Acanthopanacis Senticosi has another name called " Radix Acanthopanacis Senticosi ", and Radix Notoginseng has another name called " Radix Notoginseng ", and the two is with monarch drug Radix Salviae Miltiorrhizae prescription, adds suitable amount of sucrose and dextrin is gained the name three ginseng grains in Chinese medicine extract.It is clinically used for coronary heart diseases and angina pectoris, apoplexy sequela etc..Clinical practice more than 30 year, determined curative effect.But it has preparation technology and falls behind, quality is uncontrollable, the shortcoming that supplementary product consumption is relatively big and preparation stability is bad, and the proportioning about three ginseng Chinese medicine compositions is unreasonable, can not give full play to three taste Chinese medicines synergism in treatment cardiovascular disease in three ginsengs.
Summary of the invention
An object of the present invention is in that to overcome the deficiencies in the prior art, it is provided that a kind of Chinese medicinal granular formulation treating cardiovascular disease.
The Chinese medicinal granular formulation of the present invention is made up of Chinese medicine extract and adjuvant.The weight ratio of described Chinese medicine extract and adjuvant is 10:0.8～1.5；Described Chinese medicine extract by weight portion is: Radix Salviae Miltiorrhizae 30 parts, Radix Notoginseng 10 parts and Radix Et Caulis Acanthopanacis Senticosi 20 parts are made, and described adjuvant is the hydroxypropyl methyl cellulose of the pregelatinized Starch of 1～5 weight portion, the HP-β-CD of 5～10 weight portions, the Aspartame of 0.5 weight portion and 1～5 weight portion.
Further carry out in scheme in the present invention, the weight ratio of described Chinese medicine extract and adjuvant is preferably 10:1, and the weight portion of described adjuvant is preferably the hydroxypropyl methyl cellulose of the pregelatinized Starch of 3 weight portions, the HP-β-CD of 8 weight portions, the Aspartame of 0.5 weight portion and 2 weight portions.
It is a further object to provide a kind of method preparing described Chinese medicinal granular formulation, specifically comprise the following steps that
(1) red rooted salvia of corresponding weight portion is taken, the alcohol reflux with the 90% of 8 times amount 1.5 hours, extracts 2 times, filters, concentrating under reduced pressure, obtain tanshinol extracted extract；By the filtering residue soak by water 1 hour with 8 times amount, extract 2 times, filter, concentrating under reduced pressure, obtain Salvia miltiorrhiza Bge water extracted extract；
(2) take Radix Et Caulis Acanthopanacis Senticosi and the Radix Notoginseng of corresponding weight portion, extract 2 hours with 75% alcohol heating reflux, extract 2 times, filter, concentrating under reduced pressure, obtain the alcohol-extracted extract of Radix Et Caulis Acanthopanacis Senticosi and Radix Notoginseng,
(3) extractum in step 1 and 2 is merged, drying under reduced pressure, mix and obtain described Chinese medicine extract；
(4) Chinese medicine extract obtained in step 3 adds the auxiliary materials and mixing of corresponding weight portion, makes soft material with 60% ethanol as wetting agent, granulate, dry, to obtain final product.
Three traditional ginseng electuaries are optimized by the present invention by lot of experiments research, greatly improve drug effect；There is great clinical value, give certain enlightenment effect to the synergism improving Chinese medicine compound.In addition, the present invention gropes to obtain the preferred plan of ratio of adjuvant and consumption by lot of experiments research, adopt above-mentioned adjuvant can overcome the hygroscopic problem of extractum, and improve the stability of three ginseng grains greatly, and content of active component in granule is stable, difference is little；Ensure that the stability of the homogeneity of compound medicine and content uniformity.
Detailed description of the invention
The detailed description present invention further below.It is pointed out that following description is only the illustration to claimed technical scheme, the not any restriction to these technical schemes.The content that protection scope of the present invention is recorded with appended claims is as the criterion.
The preparation of embodiment 1 Chinese medicine extract
(1) red rooted salvia of 30kg is taken, the alcohol reflux with the 90% of 8 times amount 1.5 hours, extracts 2 times, filters, concentrating under reduced pressure, obtain tanshinol extracted extract；By the filtering residue soak by water 1 hour with 8 times amount, extract 2 times, filter, concentrating under reduced pressure, obtain Salvia miltiorrhiza Bge water extracted extract；
(2) take Radix Et Caulis Acanthopanacis Senticosi and the 10kg Radix Notoginseng of 20kg, extract 2 hours with 75% alcohol heating reflux, extract 2 times, filter, concentrating under reduced pressure, obtain the alcohol-extracted extract of Radix Et Caulis Acanthopanacis Senticosi and Radix Notoginseng,
(3) extractum in step 1 and 2 is merged, drying under reduced pressure, mix and obtain described Chinese medicine extract 758.6g.
The preparation of embodiment 2-4 Chinese medicine granules
In the Chinese medicine extract obtained, add the auxiliary materials and mixing of corresponding weight portion, make soft material with 60% ethanol as wetting agent, granulate, dry, to obtain final product；Described Chinese medicine extract and ratio of adjuvant and adjuvant particular make-up are referring to following table:
Test example 1
(1) duplication of animal cardiac muscle ischemia model and medication
Male SD rat, body weight 250 ± 50g, often group 10.Sham operated rats: gavage the aqueous solution of equivalent；Model group: gavage the aqueous solution of equivalent；Each treated animal all gives test medicine (5ml/kg) by body weight gavage.Every day 1 time, altogether administration 7 times.It is administered latter 30 minutes at last, 1% pentobarbital sodium intraperitoneal injection of anesthesia, rat is faced upward position and is fixed on self-control Mus plate.Chest cropping, preserved skin, be embedded in left lower extremity by ECG electrode pin and right upper extremity be subcutaneous, cuts off the 4th rib in left side, by vascular forceps along the 4th rib blunt separation Intercostal muscle 3cm length, opens thoracic cavity, struts rib, heart is extruded thoracic cavity.2mm place ophthalmology pin 6-0 silk thread threading below left auricle, depth of needle is about 1-1.5mm, wide about 2-3mm, together with great cardiac vein following coronary artery occlusion left anterior descending branch (sham operated rats threading not ligation).After ligation, heart is put back to rapidly thoracic cavity.Electrocardiogram display ST section greatly drives up or during abnormality Q wave;Namely acute myocardial ischemia modeling success is shown.Sew up rapidly thoracic wall, stop artificial respiration, remove respiratory secretions, sew up and close trachea, put to death after 24h.The ligation 10min ECG ST section person of being not changed in eliminates.
The mensuration of myocardial ischemia infarct size percentage ratio: postoperative 24h, postanesthetic rat is opened thoracic cavity, take off rapidly heart, put-20 DEG C of freezing 20min, below ligature, left ventricle is cut into the 4-5 sheet that thickness is 2mm, put in 1%TTC solution, dye 15min when 37 DEG C of water-baths, lucifuges, infarcted region not painted (white), and redness is dyed in non-infarcted region, 1% paraformaldehyde fixes 12h, according to formula 1 Image-J (NIH) computed in software Infarct area percentage ratio.Myocardial infarction area percentage ratio (S) %=Infarct area/left ventricle gross area × 100%.
Left room hemodynamic index measures: postoperative 24h, is again anaesthetized by rats by intraperitoneal injection 1% pentobarbital sodium (50mg/kg), then intravenous injection heparin whole body anticoagulant, and physiograph detection cardiac hemodynamic parameter is applied in operation after separating right common carotid artery.Intubate to left ventricular recording pressure curve, record left room maximum collapse (+) and diastole (-) speed (± dp/dtmax).
(2) concrete outcome is as follows:
In all test examples, in order to the effect of the present invention is described, spy arranges four comparative examples, specific as follows:
Comparative example 1: Radix Salviae Miltiorrhizae: Radix Notoginseng: the weight proportion of Radix Et Caulis Acanthopanacis Senticosi is 30:5:15, and preparation method is with embodiment 1；
Comparative example 2: Radix Salviae Miltiorrhizae: Radix Notoginseng: the weight proportion of Radix Et Caulis Acanthopanacis Senticosi is 30:25:30, and preparation method is with embodiment 1；
Comparative example 3: referring to the embodiment 2 in patent CN101085008A；Radix Salviae Miltiorrhizae: Radix Notoginseng: the weight proportion of Radix Et Caulis Acanthopanacis Senticosi is 20:2:3；
Comparative example 4: referring to three ginseng electuaries, Radix Salviae Miltiorrhizae: Radix Notoginseng: the weight proportion of Radix Et Caulis Acanthopanacis Senticosi is 25:1:1 in " Heilongjiang Provincial Hospital's preparation specification "；
Myocardial ischemia infarct size:
* or * * be medicine group compared with model group, T check P < 0.05 or 0.01, T inspection P < 0.05 or 0.01.
Left room hemodynamic index:
* or * * be medicine group compared with model group, T check P < 0.05 or 0.01, T inspection P < 0.05 or 0.01.
The test example 2 impact on rat myocardial cell
(1) rat myocardial cell primary culture method: take out the SD neonatal rat 25 in raw 24h, after heart all takes out, rejecting blood clotting and the fibrous tissue of heart periphery, Digestive system (0.125% pancreatin+0.05% II Collagenase Type) digests, and collects cell, it is filtered to remove and does not digest tissue, it is inoculated in culture bottle, puts in cell culture incubator (37 DEG C, 95%O2+5%CO2) and cultivate, fibrocyte, purification myocardial cell is removed with differential attachment method.After 2h, the not yet adherent cell suspension of sucking-off blows even, adjusts density and implants (every hole 500 μ l) in 24 orifice plates to 1 × 10-6, makes cell be uniformly distributed, and adds Brdu to 0.1mmol/L, 24h and changes liquid once, and every 3-4d changes liquid once later.The regularly situation of observation of cell growth under inverted microscope, after cultivating 48h, random packet is tested.
Cell is inoculated in 24 orifice plates with the density of 1 × 106/ml, every hole 500 μ l.37 DEG C, 5%CO2 saturated humidity when cultivate.After primary myocardial cell culture 72h, Normal group and model group are normally cultivated with 500 μ lDMEM culture fluid, each administration group adds the DMEM culture fluid containing 10% medicinal liquid, after hatching 6h, rinsing 2 times with ice-cold PBS, model group and the every hole of administration group add 500 μ l through Tyrode liquid saturated for 95%N2-5%O2, then culture plate is put into a hermetic container, continuing to pass to hermetic container after mixing gas (95%N2-5%O2) 30min, put into incubator anoxia 12h, simulation is at body ischemia model.Normal group adds cultivation 12h in Tyrode liquid 500 μ l, the CO2 incubator containing 10g/L glucose after cleaning old culture medium.
Every hole adds final concentration of 0.5mg/mlMTT serum-free DMEM culture fluid 500 μ l and cultivates 4h, then incline supernatant, adds the DMSO of 500 μ l, jolting 10min, the absorbance (OD570nm) at 570nm place is measured, for quantitative cell survival rate by full-automatic microplate reader.
200 μ l culture supernatant are drawn in the every hole of culture plate after processing, illustrates according to LDH detection kit, detect LDH activity.
(2) concrete outcome is as follows:
The impact on the rat myocardial cell of Anoxia of each single medicinal material, by Radix Salviae Miltiorrhizae extract for Radix Salviae Miltiorrhizae alcohol extraction and the water extracted immersing paste being mixed and get final product, the extract of two taste medicines is extracted and obtained to Radix Et Caulis Acanthopanacis Senticosi and Radix Notoginseng respectively, and the preparation method of each extract is with embodiment 1.
Cell survival rate (MTT) and LDH activity:
Test example 3 stability test
Investigate correlated samples stability according to the stability guideline of 2010 editions two annex of Chinese Pharmacopoeia, investigated respectively, place the medicine stability of 60 days under 25 DEG C and relative humidity 75% condition.HPLC method is adopted to measure the content of syringoside, tanshinone ⅡA and salvianolic acid B in granule.
It addition, be the superiority embodying granule of the present invention, ad hoc fixed following comparative example:
Comparative example 1: without any adjuvant, other are with embodiment 2；
Comparative example 2: adjuvant is hydroxypropyl methyl cellulose, consumption and other are with embodiment 3；
Comparative example 3: Chinese medicine extract and supplementary product consumption are than for 10:2, and other are with embodiment 3；
The weight ratio of 4: four kinds of adjuvants of comparative example is 1:1:0.1:0.5, and other are with embodiment 3；
The weight ratio of 5: four kinds of adjuvants of comparative example is 1:6:0.5:2, and other are with embodiment 3；
Each group Effective Component of Chinese Medicine content (n=10) after placing 60 days under 25 DEG C and relative humidity 75% condition
It addition, sample after taking above-mentioned test, requiring to carry out detection disintegration with reference to 2010 editions annex XIIA of Chinese Pharmacopoeia, result is as follows:
Place 60 days under 25 DEG C and relative humidity 75% condition
Embodiment 5
Adopt fixed funnel method (Xi Nianzhu edits " pharmaceutics " third edition) to measure the angle of repose of granule before sample fill, and measure the granularity qualification rate of sample.Granularity qualification rate=[weight of conforming particle/(weight of the weight+adjuvant of dry extract)] X100%；Conforming particle standard can pass through a sieve can not pass through the granule of No. four sieves.
Result is as follows:
Present invention merely illustrates some claimed specific embodiments; technical characteristic described in one of them or more technical scheme can be combined with arbitrary one or more technical schemes; the technical scheme that these are combined and obtain is also in the application protection domain, technical scheme that is combined just as these and that obtain specifically has been recorded in the disclosure of invention.
Claims (3)
1. the Chinese medicinal granule treating cardiovascular disease, it is characterised in that be made up of Chinese medicine extract and adjuvant；The weight ratio of described Chinese medicine extract and adjuvant is 10:1；Described Chinese medicine extract by weight portion is: Radix Salviae Miltiorrhizae 30 parts, Radix Notoginseng 10 parts and Radix Et Caulis Acanthopanacis Senticosi 20 parts are made, and described adjuvant is the hydroxypropyl methyl cellulose of the pregelatinized Starch of 3 weight portions, the HP-β-CD of 8 weight portions, the Aspartame of 0.5 weight portion and 2 weight portions.
2. the preparation method of Chinese medicinal granule described in a claim 1, it is characterised in that: specifically comprise the following steps that
(1) take the red rooted salvia of corresponding weight portion, with the alcohol reflux 1.5 hours of the 70%-95% of 6-10 times amount, extract 2 times, filter, concentrating under reduced pressure, obtain tanshinol extracted extract；By the filtering residue soak by water 1 hour with 6-10 times amount, extract 2 times, filter, concentrating under reduced pressure, obtain Salvia miltiorrhiza Bge water extracted extract；
(2) take Radix Et Caulis Acanthopanacis Senticosi and the Radix Notoginseng of corresponding weight portion, extract 2 hours with 70-90% alcohol heating reflux, extract 2 times, filter, concentrating under reduced pressure, obtain the alcohol-extracted extract of Radix Et Caulis Acanthopanacis Senticosi and Radix Notoginseng；
(3) extractum in step 1 and 2 is merged, drying under reduced pressure, mix and obtain described Chinese medicine extract；
(4) Chinese medicine extract obtained in step 3 adds the auxiliary materials and mixing of corresponding weight portion, makes soft material with 60% ethanol as wetting agent, granulate, dry, to obtain final product.
3. the application in preparation treatment cardiovascular disease medicine of the Chinese medicinal granule described in a claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410321506.2A CN104306437B (en) | 2014-07-08 | 2014-07-08 | A kind of for Chinese medicinal granular formulation treating cardiovascular disease and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410321506.2A CN104306437B (en) | 2014-07-08 | 2014-07-08 | A kind of for Chinese medicinal granular formulation treating cardiovascular disease and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104306437A CN104306437A (en) | 2015-01-28 |
| CN104306437B true CN104306437B (en) | 2016-06-29 |
Family
ID=52361846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410321506.2A Expired - Fee Related CN104306437B (en) | 2014-07-08 | 2014-07-08 | A kind of for Chinese medicinal granular formulation treating cardiovascular disease and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104306437B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085008A (en) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | Composition containing acanthopanax root for treating cardiovascular diseases and its preparation |
-
2014
- 2014-07-08 CN CN201410321506.2A patent/CN104306437B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085008A (en) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | Composition containing acanthopanax root for treating cardiovascular diseases and its preparation |
Non-Patent Citations (1)
| Title |
|---|
| 中医药治疗心血管疾病循证医学研究进展;袁兆明;《辽宁中医药大学学报》;20110131;第13卷(第1期);16-18 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104306437A (en) | 2015-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103816280B (en) | Traditional Chinese medicine composition for treating myocardial infarction and application of traditional Chinese medicine composition | |
| EP2353602A2 (en) | Natural pharmaceutical preparations for increasing albumin | |
| CN104225217A (en) | Chinese herba preparation for treating coronary heart disease and preparation method thereof | |
| WO2004096249A1 (en) | A composition containing radix codonopsis pilosulae and radix astragali and hedysari, method of producing it and use thereof | |
| CN102416101B (en) | Chinese medicinal composition for treating heart failure and preparation method thereof | |
| CN102526423A (en) | Medicine composition for treating ischemic heart disease | |
| CN101099775B (en) | Cardiac and cerebral vascular disease treating medicine | |
| CN105902827A (en) | Traditional Chinese medicine composition for improving immunity of human body and preparation method thereof | |
| CN104306437B (en) | A kind of for Chinese medicinal granular formulation treating cardiovascular disease and preparation method thereof | |
| CN1970050B (en) | Pharmaceutical composition for treating arrhythmia and preparation process thereof | |
| CN102068520B (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN101062027B (en) | Taurine and medical combination for treating cardiovascular and cerebrovascular diseases | |
| CN104740054B (en) | A kind of pharmaceutical composition for preventing and treating myocardial ischemia and its production and use | |
| CN107343925B (en) | Traditional Chinese medicine composition for treating chronic heart failure and preparation method thereof | |
| CN101744938B (en) | Pharmaceutical composition and preparation method thereof | |
| CN104161800B (en) | It is a kind of to be used to treat Chinese medicine composition of angiocardiopathy and preparation method thereof | |
| CN104069174B (en) | A kind of pharmaceutical composition and its production and use | |
| CN109568481A (en) | A kind of Chinese prescription preparation for treating coronary heart disease | |
| CN101152246B (en) | Pharmaceutical composition for cardiovascular and cerebrovascular diseases and method for preparing the same | |
| CN1325509C (en) | Extract of american ginseng fruit saponin, extracting and refining method and medicinal use thereof | |
| CN107184760B (en) | Chinese medicinal composition for treating cardiovascular diseases and preparation method thereof | |
| CN108653559A (en) | A kind of hypoglycemic composition and its application | |
| CN100384439C (en) | Medicinal composition for treating and/or preventing heart brnin blood vessel disease and its preparation method | |
| CN113413424B (en) | Preparation method and application of lucid ganoderma oral liquid | |
| CN104189288B (en) | A kind of Chinese medicine composition for treating myocardial infarction and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Zhenyu Inventor after: Sun Yanping Inventor after: Li Zhenxu Inventor before: Li Zhenyu Inventor before: Sun Yanping Inventor before: Zheng Xiuqian |
|
| COR | Change of bibliographic data | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160629 |